Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Early Breast Cancer”

104 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 104 results

Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Not applicableLooking for participantsNCT06050109
What this trial is testing

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

Who this might be right for
Breast Cancer FemaleEndocrine Therapy
Hongmei Zheng, PhD 1,200
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Not applicableLooking for participantsNCT06185569
What this trial is testing

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon 4,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661
What this trial is testing

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 109
Testing effectiveness (Phase 2)Ended earlyNCT01919229
What this trial is testing

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Looking for participantsNCT07581834
What this trial is testing

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Who this might be right for
Breast DiseasesBreast NeoplasmsDalpiciclib+3 more
Fujian Cancer Hospital 2,000
Not applicableLooking for participantsNCT07084558
What this trial is testing

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Who this might be right for
Early and Locally Advanced Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 350
Not applicableStudy completedNCT07052734
What this trial is testing

Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Sun Yat-sen University 2,843
Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Post-approval studies (Phase 4)UnknownNCT05302336
What this trial is testing

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast CancerChemotherapeutic Toxicity
Second Affiliated Hospital, Zhejiang University, School of Medicine 402
Not applicableNot Yet RecruitingNCT07484763
What this trial is testing

Predicting Recurrence in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer, HR+/HER2- Early-Stage
Shengjing Hospital 500
Not applicableStudy completedNCT06619704
What this trial is testing

Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 194
Testing effectiveness (Phase 2)Looking for participantsNCT05306041
What this trial is testing

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GBG Forschungs GmbH 170
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Next Page